The data represent the longest follow-up available for spinal cord stimulation at a frequency higher than 60 Hz, which was the frequency initially approved by the FDA.
The Food and Drug Administration has approved Abbott s Proclaim XR spinal cord stimulation system for the treatment of diabetic peripheral neuropathy, the company announced.
Patients with diabetic neuropathy may have difficulty chewing, which may interfere with their ability to follow nutrition advice for optimal blood glucose control, a small study in Japan suggests.
Diabetic peripheral neuropathy (DPN) affects over half of type 2 diabetes mellitus (T2DM) patients, with an urgent need for effective pharmacotherapies. While many rat and mouse models of T2DM exist, the phenotyping of DPN has been challenging with inconsistencies across laboratories. To better characterize DPN in rodents, a consensus guideline was published in 2014 to accelerate the translation of preclinical findings. Here we review DPN phenotyping in rat models of T2DM against the ‘Neurodiab’ criteria to identify uptake of the guidelines and discuss how DPN phenotypes differ between models and according to diabetes duration and sex. A search of PubMed, Scopus and Web of Science databases identified 125 studies, categorised as either diet and/or chemically induced models or transgenic/spontaneous models of T2DM. The use of diet and chemically induced T2DM models has exceeded that of transgenic models in recent years, and the introduction of the Neurodiab guidelines has not apprec